These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1154 related articles for article (PubMed ID: 15827035)

  • 1. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea.
    Lee MC; Lee S; Suh DC; Kim J; Kong SX;
    Curr Med Res Opin; 2003; 19(7):597-602. PubMed ID: 14606981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Verification of a decision analytic model assumption using real-world practice data: implications for the cost effectiveness of cyclo-oxygenase 2 inhibitors (COX-2s).
    Cox ER; Motheral B; Mager D
    Am J Manag Care; 2003 Dec; 9(12):785-94. PubMed ID: 14712755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical experience with cyclooxygenase-2 inhibitors.
    Lanas A
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():16-22; discussion 35-42. PubMed ID: 12173276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecific NSAIDs and COX-2-specific inhibitors.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S401-13. PubMed ID: 12416790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
    Hochberg MC
    Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What are the risks of long-term NSAIDs and COX-2 inhibitors?
    DeBisschop M
    J Fam Pract; 2003 Mar; 52(3):199-200. PubMed ID: 12620173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A; Krahn M; Naglie G
    Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Drug Events Involving COX-2 Inhibitors.
    Verrico MM; Weber RJ; McKaveney TP; Ansani NT; Towers AL
    Ann Pharmacother; 2003 Sep; 37(9):1203-13. PubMed ID: 12921500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use.
    Laine L; Connors LG; Reicin A; Hawkey CJ; Burgos-Vargas R; Schnitzer TJ; Yu Q; Bombardier C
    Gastroenterology; 2003 Feb; 124(2):288-92. PubMed ID: 12557133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inadequate prevention of NSAID-induced gastrointestinal events.
    Herings RM; Goettsch WG
    Ann Pharmacother; 2004 May; 38(5):760-3. PubMed ID: 15031416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug utilization review of celecoxib in Ontario.
    LeLorier J; Fitzsimon C; Keresteci M; Stewart D; Lavoie F
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii11-6. PubMed ID: 14585913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population.
    Rahme E; Marentette MA; Kong SX; Lelorier J
    Arthritis Rheum; 2002 Dec; 47(6):595-602. PubMed ID: 12522832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteoarthritis therapy--are there still unmet needs?
    Laufer S
    Rheumatology (Oxford); 2004 Feb; 43 Suppl 1():i9-15. PubMed ID: 14752170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COX-2 inhibitors.
    Brooks PM; Day RO
    Med J Aust; 2000 Oct; 173(8):433-6. PubMed ID: 11090038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study.
    Nørgård B; Pedersen L; Johnsen SP; Tarone RE; McLaughlin JK; Friis S; Sørensen HT
    Aliment Pharmacol Ther; 2004 Apr; 19(7):817-25. PubMed ID: 15043523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
    Wolfe F; Michaud K; Burke TA; Zhao SZ
    J Rheumatol; 2004 Feb; 31(2):355-8. PubMed ID: 14760808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 58.